Updated Standard of Care Clinical Guidelines

Updated Standard of Care Clinical Guidelines Point to Cairn Diagnostics’ Breath Test for Evaluating Gastric Emptying and Diagnosing Gastroparesis Brentwood, Tenn. —  September 13, 2023  — Cairn Diagnostics, an innovative leader in providing cutting-edge FDA-approved breath tests intended for routine use in diagnostic medicine, today announced the inclusion of its 13C-Spirulina Gastric Emptying Breath Test…

Details

Cairn Diagnostics Delivers Virtual Administration of its Novel 13C-Spirulina Gastric Emptying Breath Test

Cairn Diagnostics Delivers Virtual Administration of its Novel 13C-Spirulina Gastric Emptying Breath Test Brentwood, Tenn. — September 14, 2021 — Cairn Diagnostics, an innovative leader in providing cutting-edge breath tests intended for routine use in diagnostic medicine, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of the Company’s 13C-Spirulina…

Details

FDA Approved Breath Test To Aid In Diagnosis of Delayed Gastric Emptying

Brentwood, Tenn. — September 14, 2021 — Cairn Diagnostics, an innovative leader in providing cutting-edge breath tests intended for routine use in diagnostic medicine, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of the Company’s 13C-Spirulina Gastric Emptying Breath Test (GEBT) to now include “at home” administration under virtual supervision of Cairn…

Details